NasdaqGM:OBLN

Stock Analysis Report

Executive Summary

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight.

Snowflake

Fundamentals

Imperfect balance sheet with limited growth.

Risks

  • Obalon Therapeutics has significant price volatility in the past 3 months.

Similar Companies

Share Price & News

How has Obalon Therapeutics's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-8.7%

NasdaqGM:OBLN

-1.9%

US Medical Equipment

-1.9%

US Market


1 Year Return

-92.1%

NasdaqGM:OBLN

10.2%

US Medical Equipment

-3.3%

US Market

OBLN underperformed the Medical Equipment industry which returned 10.2% over the past year.

OBLN underperformed the Market in United States of America which returned -3% over the past year.


Share holder returns

OBLNIndustryMarket
7 Day-8.7%-1.9%-1.9%
30 Day-66.0%-2.8%-6.2%
90 Day-67.4%7.6%0.3%
1 Year-92.1%-92.1%11.1%10.2%-1.1%-3.3%
3 Yearn/a64.7%59.6%37.9%28.9%
5 Yearn/a127.0%101.0%50.8%34.1%

Price Volatility Vs. Market

How volatile is Obalon Therapeutics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Obalon Therapeutics undervalued based on future cash flows and its price relative to the stock market?

0.93x

Price to Book (PB) ratio


Intrinsic Value Based on Future Cash Flows

Unable to calculate intrinsic value for Obalon Therapeutics to establish if it is available at moderate discount.

Unable to calculate intrinsic value for Obalon Therapeutics to establish if it is available at substantial discount.


Price Based on Earnings

Obalon Therapeutics is loss making, we can't compare its value to the US Medical Equipment industry average.

Obalon Therapeutics is loss making, we can't compare the value of its earnings to the United States of America market.


Price Based on Expected Growth

Unable to calculate PEG ratio for Obalon Therapeutics, we can't assess if its growth is good value.


Price Based on Value of Assets

Obalon Therapeutics is good value based on assets compared to the US Medical Equipment industry average.


Next Steps

Future Growth

How is Obalon Therapeutics expected to perform in the next 1 to 3 years based on estimates from 4 analysts?

20.1%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

Obalon Therapeutics's revenue is expected to grow significantly at over 20% yearly.

Obalon Therapeutics is not considered high growth as it is expected to be loss making for the next 1-3 years.

Obalon Therapeutics's revenue growth is expected to exceed the United States of America market average.

Unable to compare Obalon Therapeutics's earnings growth to the United States of America market average as it is expected to be loss making during the next 1-3 years.

Unable to compare Obalon Therapeutics's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if Obalon Therapeutics will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has Obalon Therapeutics performed over the past 5 years?

-25.8%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Obalon Therapeutics does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare Obalon Therapeutics's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare Obalon Therapeutics's 1-year growth to the US Medical Equipment industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if Obalon Therapeutics has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if Obalon Therapeutics has efficiently used its assets last year compared to the US Medical Equipment industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if Obalon Therapeutics improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is Obalon Therapeutics's financial position?


Financial Position Analysis

Obalon Therapeutics is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

Obalon Therapeutics's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

Obalon Therapeutics's level of debt (59.6%) compared to net worth is high (greater than 40%).

Unable to establish if Obalon Therapeutics's debt level has increased without past 5-year debt data.


Balance Sheet

High level of physical assets or inventory.

Debt is covered by short term assets, assets are 3.4x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Obalon Therapeutics has less than a year of cash runway based on current free cash flow.

Obalon Therapeutics has less than a year of cash runway if free cash flow continues to grow at historical rates of 17% each year.


Next Steps

Dividend

What is Obalon Therapeutics's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate Obalon Therapeutics's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate Obalon Therapeutics's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as Obalon Therapeutics has not reported any payouts.

Unable to verify if Obalon Therapeutics's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as Obalon Therapeutics has not reported any payouts.


Future Payout to Shareholders

Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.


Next Steps

Management

What is the CEO of Obalon Therapeutics's salary, the management and board of directors tenure and is there insider trading?

0.6yrs

Average management tenure


CEO

Obalon Therapeutics has no CEO, or we have no data on them.


Management Age and Tenure

0.6yrs

Average Tenure

53.5yo

Average Age

The average tenure for the Obalon Therapeutics management team is less than 2 years, this suggests a new team.


Board Age and Tenure

3.5yrs

Average Tenure

56.5yo

Average Age

The tenure for the Obalon Therapeutics board of directors is about average.


Insider Trading

More shares have been bought than sold by Obalon Therapeutics individual insiders in the past 3 months.


Recent Insider Transactions

BuyUS$50,00008 Aug 19
Kim Kamdar
EntityIndividual
Role
Member of the Board of Directors
Director
Shares12,500
Max PriceUS$4.00
BuyUS$1,000,00008 Aug 19
Domain Associates, L.L.C.
EntityCompany
Shares250,000
Max PriceUS$4.00
BuyUS$20,00008 Aug 19
Nooshin Hussainy
EntityIndividual
Shares5,000
Max PriceUS$4.00
BuyUS$20,00008 Aug 19
Robert Macdonald
EntityIndividual
Role
Senior Key Executive
Chief Retail Officer
Shares5,000
Max PriceUS$4.00
BuyUS$20,00008 Aug 19
Mark Brister
EntityIndividual
Role
Chief Technology Officer
Chief Technology Officer
Shares5,000
Max PriceUS$4.00
BuyUS$50,00008 Aug 19
Andrew Rasdal
EntityIndividual
Role
Chairman of the Board
Executive Chairman of the Board
Shares12,500
Max PriceUS$4.00
BuyUS$10,00008 Aug 19
Amy VandenBerg
EntityIndividual
Role
Senior Key Executive
Chief Quality Assurance
Shares2,500
Max PriceUS$4.00
BuyUS$50,00008 Aug 19
William Plovanic
EntityIndividual
Role
Member of the Board of Directors
President
Shares12,500
Max PriceUS$4.00
BuyUS$25,00008 Aug 19
Lesley Howe
EntityIndividual
Role
Member of the Board of Directors
Director
Shares6,250
Max PriceUS$4.00
BuyUS$30,00008 Aug 19
Sharon Stevenson
EntityIndividual
Role
Member of the Board of Directors
Director
Shares7,500
Max PriceUS$4.00
BuyUS$100,00008 Aug 19
InterWest Partners LLC
EntityCompany
Shares25,000
Max PriceUS$4.00

Ownership Breakdown


Management Team

  • Andy Rasdal (61yo)

    Executive Chairman of the Board

    • Tenure: 0.6yrs
    • Compensation: US$2.32m
  • Mark Brister (57yo)

    Chief Technology Officer

    • Tenure: 2.8yrs
    • Compensation: US$486.81k
  • William Plovanic (50yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$1.07m
  • Kelly Huang (50yo)

    Consultant

    • Tenure: 0.3yrs
    • Compensation: US$1.13m
  • Amy VandenBerg (44yo)

    Chief Quality Assurance

    • Tenure: 0.6yrs
    • Compensation: US$347.89k
  • Robert Mondore (46yo)

    Vice President of Operations

    • Tenure: 1.3yrs
  • Daina Schmidt (57yo)

    Vice President of Marketing

    • Tenure: 0.8yrs
  • Bob Macdonald (59yo)

    Chief Retail Officer

    • Tenure: 0.3yrs

Board Members

  • Andy Rasdal (61yo)

    Executive Chairman of the Board

    • Tenure: 0.6yrs
    • Compensation: US$2.32m
  • Sharon Stevenson (70yo)

    Director

    • Tenure: 11.6yrs
    • Compensation: US$142.44k
  • Ray Dittamore (76yo)

    Director

    • Tenure: 3.4yrs
    • Compensation: US$154.94k
  • Les Howe (74yo)

    Director

    • Tenure: 3.6yrs
    • Compensation: US$157.44k
  • Kim Kamdar (52yo)

    Director

    • Tenure: 11.6yrs
    • Compensation: US$169.94k
  • Doug Fisher (43yo)

    Director

    • Tenure: 7.3yrs
    • Compensation: US$139.94k
  • William Plovanic (50yo)

    President

    • Tenure: 0.3yrs
    • Compensation: US$1.07m
  • David Moatazedi (41yo)

    Director

    • Tenure: 2.4yrs
    • Compensation: US$147.44k

Company Information

Obalon Therapeutics, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Obalon Therapeutics, Inc.
  • Ticker: OBLN
  • Exchange: NasdaqGM
  • Founded: 2008
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$12.252m
  • Shares outstanding: 5.54m
  • Website: https://www.obalon.com

Number of Employees


Location

  • Obalon Therapeutics, Inc.
  • 5421 Avenida Encinas
  • Suite F
  • Carlsbad
  • California
  • 92008
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
OBLNNasdaqGM (Nasdaq Global Market)YesCommon SharesUSUSDOct 2016
24OADB (Deutsche Boerse AG)YesCommon SharesDEEUROct 2016

Biography

Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people who are obese and overweight. The company offers the Oba ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/25 00:47
End of Day Share Price2019/08/23 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.